申请人:CV Therapeutics, Inc.
公开号:US20020037872A1
公开(公告)日:2002-03-28
N
6
heterocyclic 5′ modified adenosine derivatives that are adenosine A
1
receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
N6杂环5'-修饰腺苷衍生物是腺苷A1受体的部分或全激动剂,因此对于修饰心脏活动、修饰脂肪细胞功能、治疗中枢神经系统疾病、治疗哺乳动物的糖尿病和肥胖症,特别是人类,具有用途。